Transdermal Gel Offers New Option for Gout
By Alesia Wagner, Chain Drug Review
Gout, an extremely painful form of inflammatory arthritis, affects more than 4% of Americans and about 10% of men over the age of 60. It is more common in women after menopause. The disease occurs due to an excess of the bodily waste uric acid. The acid is deposited as needle-like crystals in the joints or in soft tissue. These crystals cause redness, swelling, stiffness and intense pain in the joints, which in turn can create gout flares.
ColciGel is a new prescription medication for the treatment of acute flares of gout. It is a transdermal gel that contains homeopathic colchicine (colchicinum 4X) that is applied directly to the sites of a flare. ColciGel penetrates the dermal layer, resulting in the reduction of inflammation and pain associated with the flare.
